INT110817

From wiki-pain
Revision as of 10:25, 23 September 2012 by Daniel (Talk | contribs)

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to: navigation, search
Context Info
Confidence 0.35
First Reported 2002
Last Reported 2008
Negated 0
Speculated 0
Reported most in Body
Documents 3
Total Number 3
Disease Relevance 2.75
Pain Relevance 0.36

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

SCLC1 (Homo sapiens)
Pain Link Frequency Relevance Heat
palliative 1 88.24 High High
aspirin 50 76.44 Quite High
cINOD 13 62.16 Quite High
methotrexate 1 41.36 Quite Low
Inflammation 2 27.36 Quite Low
vincristine 8 5.00 Very Low Very Low Very Low
Analgesic 3 5.00 Very Low Very Low Very Low
Angina 1 5.00 Very Low Very Low Very Low
alcohol 1 5.00 Very Low Very Low Very Low
tolerance 1 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Small Cell Lung Cancer 39 100.00 Very High Very High Very High
Toxicity 19 98.48 Very High Very High Very High
Disease 20 98.44 Very High Very High Very High
Non-small-cell Lung Cancer 7 98.00 Very High Very High Very High
Lung Cancer 36 96.48 Very High Very High Very High
Disease Progression 1 85.80 High High
Death 1 80.84 Quite High
Anaemia 6 77.60 Quite High
Thrombocytopenia 10 76.56 Quite High
Neutropenia 14 75.32 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Topotecan is a novel topoisomerase I inhibitor with established antitumor activity in recurrent SCLC and has a predictable, noncumulative toxicity profile.
Negative_regulation (inhibitor) of SCLC associated with toxicity and small cell lung cancer
1) Confidence 0.35 Published 2003 Journal Lung Cancer Section Abstract Doc Link 12781421 Disease Relevance 1.24 Pain Relevance 0.09
Our data are partly in contrast to these results, in that we observed the most marked reduction for SCLC, but also a significant decrease in risk for all NSCLC subtypes combined.
Negative_regulation (reduction) of SCLC associated with non-small-cell lung cancer and small cell lung cancer
2) Confidence 0.23 Published 2002 Journal BMC Cancer Section Body Doc Link PMC138809 Disease Relevance 0.58 Pain Relevance 0.28
Topotecan, a topoisomerase I inhibitor, is an active drug in relapsed SCLC.
Negative_regulation (inhibitor) of SCLC associated with small cell lung cancer
3) Confidence 0.13 Published 2008 Journal OncoTargets and therapy Section Body Doc Link PMC2994215 Disease Relevance 0.93 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox